Amphastar Pharmaceuticals Return on Tangible Equity 2012-2026 | AMPH
Current and historical return on tangible equity values for Amphastar Pharmaceuticals (AMPH) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Amphastar Pharmaceuticals Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2026-03-31 | $0.08B | $0.21B | 38.00% |
| 2025-12-31 | $0.10B | $0.19B | 50.13% |
| 2025-09-30 | $0.11B | $0.17B | 64.07% |
| 2025-06-30 | $0.13B | $0.16B | 86.31% |
| 2025-03-31 | $0.14B | $0.14B | 101.81% |
| 2024-12-31 | $0.16B | $0.11B | 140.71% |
| 2024-09-30 | $0.16B | $0.08B | 186.90% |
| 2024-06-30 | $0.17B | $0.05B | 370.95% |
| 2024-03-31 | $0.15B | $0.01B | 1987.10% |
| 2023-12-31 | $0.14B | $0.12B | 114.88% |
| 2023-09-30 | $0.14B | $0.24B | 57.32% |
| 2023-06-30 | $0.10B | $0.36B | 28.45% |
| 2023-03-31 | $0.09B | $0.48B | 19.25% |
| 2022-12-31 | $0.09B | $0.47B | 19.55% |
| 2022-09-30 | $0.08B | $0.45B | 17.32% |
| 2022-06-30 | $0.09B | $0.43B | 21.40% |
| 2022-03-31 | $0.08B | $0.42B | 19.69% |
| 2021-12-31 | $0.06B | $0.41B | 15.40% |
| 2021-09-30 | $0.04B | $0.41B | 9.04% |
| 2021-06-30 | $0.01B | $0.41B | 2.66% |
| 2021-03-31 | $0.00B | $0.41B | 0.74% |
| 2020-12-31 | $0.00B | $0.40B | 0.50% |
| 2020-09-30 | $0.01B | $0.40B | 1.77% |
| 2020-06-30 | $0.00B | $0.39B | 1.02% |
| 2020-03-31 | $0.05B | $0.39B | 13.39% |
| 2019-12-31 | $0.05B | $0.38B | 13.00% |
| 2019-09-30 | $0.05B | $0.36B | 14.40% |
| 2019-06-30 | $0.05B | $0.34B | 15.70% |
| 2019-03-31 | $0.00B | $0.31B | 0.65% |
| 2018-12-31 | $-0.01B | $0.30B | -2.03% |
| 2018-09-30 | $-0.01B | $0.29B | -2.44% |
| 2018-06-30 | $-0.01B | $0.28B | -3.18% |
| 2018-03-31 | $0.00B | $0.29B | -1.40% |
| 2017-12-31 | $0.00B | $0.29B | 1.40% |
| 2017-09-30 | $0.00B | $0.28B | 0.00% |
| 2017-06-30 | $0.00B | $0.28B | 1.42% |
| 2017-03-31 | $0.01B | $0.28B | 3.27% |
| 2016-12-31 | $0.01B | $0.27B | 3.73% |
| 2016-09-30 | $0.02B | $0.26B | 8.00% |
| 2016-06-30 | $0.01B | $0.25B | 5.51% |
| 2016-03-31 | $0.00B | $0.25B | 0.00% |
| 2015-12-31 | $0.00B | $0.25B | -1.22% |
| 2015-09-30 | $-0.01B | $0.24B | -5.81% |
| 2015-06-30 | $-0.02B | $0.24B | -6.66% |
| 2015-03-31 | $-0.01B | $0.24B | -4.15% |
| 2014-12-31 | $-0.01B | $0.24B | -4.69% |
| 2014-09-30 | $-0.01B | $0.23B | -2.63% |
| 2014-06-30 | $0.00B | $0.17B | -0.60% |
| 2014-03-31 | $0.01B | $0.11B | 7.57% |
| 2013-12-31 | $0.01B | $0.05B | 22.75% |
| 2013-09-30 | $0.01B | $0.05B | 29.32% |
| 2013-06-30 | $0.02B | $0.05B | 35.60% |
| 2013-03-31 | $0.01B | $0.05B | 29.32% |
| 2012-12-31 | $0.02B | $0.05B | 37.70% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.924B | $0.720B |
| Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |